In:
Ophthalmology Reports, ECO-Vector LLC, Vol. 10, No. 2 ( 2017-05-15), p. 94-109
Kurzfassung:
The article provides a brief description of diabetic macular edema pathogenesis highlighting the role of inflammation, along with a short review of aflibercept trials in diabetic macular edema patients. Three clinical cases of diabetic macular edema treatment with aflibercept (Eylea) intravitreal injections in treatment-nave patients are described; therapy was performed for 1 year according to the scheme provided in the Summary of Product Characteristics.
Materialart:
Online-Ressource
ISSN:
2412-5423
,
1998-7102
DOI:
10.17816/OV10294-109
Sprache:
Unbekannt
Verlag:
ECO-Vector LLC
Publikationsdatum:
2017